Zacks Small Cap Analysis – SNGX: Marburg Outbreak Places Concentrate on Soligenix Vaccine Growth… – Cyber Tech

By David Bautz, PhD

NASDAQ:SNGX

READ THE FULL SNGX RESEARCH REPORT

Enterprise Replace

Marburg Virus Outbreak Places Concentrate on Soligenix Vaccine Growth

Soligenix, Inc. (NASDAQ:SNGX) is creating vaccines concentrating on a number of filoviruses, together with MarVax™, a warmth secure vaccine for defense in opposition to Marburg virus. Latest occasions spotlight the significance of the corporate’s vaccine growth program.

On October 2, 2024, two tracks at a prepare station in Hamburg, Germany had been cordoned off as a result of chance {that a} traveler was contaminated with Marburg virus. A 26-year outdated German medical pupil had lately flown from Rwanda to Frankfurt and was on a prepare from Frankfurt to Hamburg when he and his girlfriend each developed flu-like signs. The coed had reportedly come into contact with a affected person in Rwanda later confirmed to be contaminated with Marburg virus.

Rwanda is presently experiencing an outbreak of Marburg virus, with 26 confirmed instances, eight deaths, and 300 individuals having been recognized as having come into shut contact with these contaminated with the virus. The World Well being Group (WHO) has suggested in opposition to all journey to Rwanda whereas the nation makes an attempt to get the outbreak below management.

Marburg marburgvirus (MARV) is a member of the Filoviridae household (that features the well-publicized Zaire ebolavirus ‘Ebola virus’) that has a mortality price as much as 88% and few therapy choices outdoors of supportive care. These viruses are carried by fruit bats and are unfold by shut contact with bodily fluids of contaminated people or with contaminated surfaces. It’s presently unclear what originated the continued outbreak in Rwanda.

Whereas accredited vaccines exist for Ebola virus (which require cold-chain storage), there aren’t any accredited vaccines or remedies for MARV. Soligenix is creating vaccines in opposition to Zaire ebolavirus, Sudan ebolavirus, and Marburg marburgvirus as monovalent and multivalent formulations. The vaccines have demonstrated very excessive efficacy, together with 100% safety in a non-human primate problem mannequin with Marburg marburgvirus, as proven within the following determine.

The vaccines are being developed utilizing the corporate’s proprietary ThermoVax™ expertise, which consists of a glycoprotein antigen from the viral floor of every virus that’s manufactured in an S2 insect cell expression system and the CoVaccine HT™ adjuvant, which is thought to stimulate each humoral (antibody) and cell-mediated (T cell) immunity. These are mixed and lyophilized to make sure stability even at elevated temperatures (40ºC) for prolonged intervals of time (no less than two years). The vaccines are being developed with assist from a Nationwide Institute of Well being (NIH) grant awarded to the College of Hawaii.

Conclusion

It seems that filovirus outbreaks will proceed to happen, thus necessitating the necessity for efficient vaccines. Soligenix’s ThermoVax expertise confers a number of benefits to its growth vaccines, together with prolonged stability at elevated temperatures, and so they have additionally proven very excessive efficacy in non-human primate fashions. We look ahead to updates from the corporate as a pre-IND assembly is anticipated to happen relating to the vaccine program within the subsequent 12 months. With no adjustments to our mannequin, our valuation stays at $35 per share.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to obtain our articles and experiences emailed on to you every morning. Please go to our web site for extra data on Zacks SCR. 

DISCLOSURE: Zacks SCR has acquired compensation from the issuer instantly, from an funding supervisor, or from an investor relations consulting agency, engaged by the issuer, for offering analysis protection for a interval of a minimum of one 12 months. Analysis articles, as seen right here, are a part of the service Zacks SCR supplies and Zacks SCR receives quarterly funds totaling a most payment of as much as $40,000 yearly for these providers supplied to or relating to the issuer. Full Disclaimer HERE.